Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab

被引：0
|
作者：
Pinheiro, Elaine M.
Hinton, Marlene
Mangadu, Ruban
Cai, Mingmei
Phan, Uyen
Nebozhyn, Michael
Hirsch, Heather
Loboda, Andrey
Javaid, Sarah
Wang, Yaolin
Sriram, Venkataraman
Phillips, Joseph H.
McClanahan, Tern
Long, Brian
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
543
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Su, Xin
    Li, Jian
    Xu, Xiao
    Ye, Youbao
    Wang, Cailiu
    Pang, Guanglong
    Liu, Wenxiu
    Liu, Ang
    Zhao, Changchun
    Hao, Xiangyong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [2] Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
    Ahn, M-J.
    Niu, J.
    Kim, D-W.
    Rasco, D.
    Mileham, K. F.
    Chung, H. C.
    Vaishampayan, U. N.
    Maurice-Dror, C.
    Lo Russo, P.
    Golan, T.
    Chartash, E.
    Chen, D.
    Healy, J.
    Rajasagi, M.
    Lee, D. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S887 - S887
  • [3] Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody
    Yao, Yunqi
    Yang, Xiaoning
    Li, Jing
    Guo, Erhong
    Wang, Huiyu
    Sun, Chunyun
    Hong, Zhangyong
    Zhang, Xiao
    Jia, Jilei
    Wang, Rui
    Ma, Juan
    Dai, Yaqi
    Deng, Mingjing
    Yu, Chulin
    Sun, Lingling
    Xie, Liangzhi
    PHARMACEUTICALS, 2025, 18 (03)
  • [4] Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
    Yue Wang
    Jingyi Han
    Dongdong Wang
    Menghua Cai
    Yi Xu
    Yu Hu
    Hui Chen
    Wei He
    Jianmin Zhang
    Signal Transduction and Targeted Therapy, 8
  • [5] Therapy of the metastatic Merkel Cell Carcinoma with the Anti-PD-1 Antibody Pembrolizumab
    Meier, K.
    Wilhelmi, J.
    Lomberg, D.
    Spaenkuch, I
    Scheu, A.
    Leiter, U.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 171 - 171
  • [6] Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
    Wang, Yue
    Han, Jingyi
    Wang, Dongdong
    Cai, Menghua
    Xu, Yi
    Hu, Yu
    Chen, Hui
    He, Wei
    Zhang, Jianmin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [7] Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
    Niu, J.
    Nagrial, A.
    Voskoboynik, M.
    Chung, H. C.
    Lee, D. H.
    Ahn, M-J.
    Bauer, T. M.
    Jimeno, A.
    Chung, V.
    Mileham, K. F.
    Chartash, E.
    Chen, D.
    Healy, J.
    Rajasagi, M.
    Maurice-Dror, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S891 - S892
  • [8] Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
    Fu, Yuyin
    Peng, Yujia
    Zhao, Shengyan
    Mou, Jun
    Zeng, Lishi
    Jiang, Xiaohua
    Yang, Chengli
    Huang, Cheng
    Li, Yuyan
    Lu, Yin
    Wu, Mengdan
    Yang, Yanfang
    Kong, Ting
    Lai, Qinhuai
    Wu, Yangping
    Yao, Yuqin
    Wang, Yuxi
    Gou, Lantu
    Yang, Jinliang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [9] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [10] Combination activity of eribulin liposomal formulation and anti-PD-1 antibody after tumor regrowth during anti-PD-1 antibody treatment in mice
    Tamura, Moe
    Niwa, Yuki
    Semba, Taro
    CANCER RESEARCH, 2024, 84 (06)
12345